Fulcrum Therapeutics (FULC) Stock Forecast for 2023 – 2026. Sell or Buy?
Updated: December 2, 2023 (12:52)
Sector: HealthcareThe share price of Fulcrum Therapeutics, Inc. (FULC) now
50/200 Day Moving Average: $3.981 / $4.209
This figure corresponds to the Average Price over the previous 50/200 days. For Fulcrum Therapeutics stocks, the 50-day moving average is the support level today.
For Fulcrum Therapeutics stocks, the 200-day moving average is the support level today.
Are you interested in Fulcrum Therapeutics, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Fulcrum Therapeutics stock price in 2023, 2024, 2025, 2026, 2027. How much will one Fulcrum Therapeutics share be worth in 2023 - 2027?
When should I take profit in Fulcrum Therapeutics stock? When should I record a loss on Fulcrum Therapeutics stock? What are analysts' forecasts for Fulcrum Therapeutics stock? What is the future of Fulcrum Therapeutics stock? We forecast Fulcrum Therapeutics stock performance using neural networks based on historical data on Fulcrum Therapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Fulcrum Therapeutics stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2023, 2024, 2025, 2026 and 2027) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Fulcrum Therapeutics shares. This happens once a day.
Historical and forecast chart of Fulcrum Therapeutics stock
The chart below shows the historical price of Fulcrum Therapeutics stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Fulcrum Therapeutics stock price can be found in the table below.
Long-term forecasts by years.
Fulcrum Therapeutics is a biopharmaceutical company that develops drugs to treat genetic diseases. The company has developed product candidates to modulate gene expression and potentially treat the underlying cause of these diseases.
Fulcrum Therapeutics daily forecast for a month
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Dec 04 | 4.96 | 4.81 | 5.10 | 6.08 |
| Dec 05 | 4.92 | 4.78 | 5.00 | 4.54 |
| Dec 06 | 4.87 | 4.78 | 4.93 | 3.18 |
| Dec 07 | 4.73 | 4.65 | 4.91 | 5.57 |
| Dec 08 | 4.79 | 4.74 | 4.97 | 4.90 |
| Dec 09 | 4.97 | 4.90 | 5.08 | 3.56 |
| Dec 10 | 4.87 | 4.81 | 5.04 | 4.76 |
| Dec 11 | 4.89 | 4.79 | 5.01 | 4.66 |
| Dec 12 | 5.04 | 4.92 | 5.15 | 4.67 |
| Dec 13 | 4.83 | 4.70 | 4.98 | 5.82 |
| Dec 14 | 4.62 | 4.47 | 4.70 | 5.11 |
| Dec 15 | 4.64 | 4.46 | 4.68 | 4.99 |
| Dec 16 | 4.78 | 4.68 | 4.89 | 4.46 |
| Dec 17 | 4.68 | 4.57 | 4.79 | 4.92 |
| Dec 18 | 4.78 | 4.68 | 4.92 | 5.05 |
| Dec 19 | 4.89 | 4.77 | 4.95 | 3.79 |
| Dec 20 | 4.80 | 4.64 | 4.93 | 6.41 |
| Dec 21 | 4.75 | 4.63 | 4.80 | 3.54 |
| Dec 22 | 4.71 | 4.63 | 4.86 | 4.93 |
| Dec 23 | 4.76 | 4.65 | 4.84 | 4.08 |
| Dec 24 | 4.75 | 4.59 | 4.84 | 5.57 |
| Dec 25 | 4.69 | 4.58 | 4.79 | 4.37 |
| Dec 26 | 4.63 | 4.51 | 4.67 | 3.70 |
| Dec 27 | 4.52 | 4.46 | 4.59 | 2.97 |
| Dec 28 | 4.50 | 4.45 | 4.63 | 4.03 |
| Dec 29 | 4.56 | 4.40 | 4.73 | 7.41 |
| Dec 30 | 4.42 | 4.28 | 4.51 | 5.36 |
| Dec 31 | 4.46 | 4.31 | 4.54 | 5.36 |
| Jan 01 | 4.26 | 4.12 | 4.37 | 5.85 |
| Jan 02 | 4.30 | 4.14 | 4.45 | 7.48 |
Fulcrum Therapeutics Daily Price Targets
Fulcrum Therapeutics Stock Forecast 12-04-2023.
Forecast target price for 12-04-2023: $4.96.
Negative dynamics for Fulcrum Therapeutics shares will prevail with possible volatility of 5.733%.
Pessimistic target level: 4.81
Optimistic target level: 5.10
Fulcrum Therapeutics Stock Forecast 12-05-2023.
Forecast target price for 12-05-2023: $4.92.
Negative dynamics for Fulcrum Therapeutics shares will prevail with possible volatility of 4.341%.
Pessimistic target level: 4.78
Optimistic target level: 5.00
Fulcrum Therapeutics Stock Forecast 12-06-2023.
Forecast target price for 12-06-2023: $4.87.
Negative dynamics for Fulcrum Therapeutics shares will prevail with possible volatility of 3.081%.
Pessimistic target level: 4.78
Optimistic target level: 4.93
Fulcrum Therapeutics Stock Forecast 12-07-2023.
Forecast target price for 12-07-2023: $4.73.
Negative dynamics for Fulcrum Therapeutics shares will prevail with possible volatility of 5.272%.
Pessimistic target level: 4.65
Optimistic target level: 4.91
Fulcrum Therapeutics Stock Forecast 12-08-2023.
Forecast target price for 12-08-2023: $4.79.
Positive dynamics for Fulcrum Therapeutics shares will prevail with possible volatility of 4.675%.
Pessimistic target level: 4.74
Optimistic target level: 4.97
Fulcrum Therapeutics Stock Forecast 12-09-2023.
Forecast target price for 12-09-2023: $4.97.
Positive dynamics for Fulcrum Therapeutics shares will prevail with possible volatility of 3.435%.
Pessimistic target level: 4.90
Optimistic target level: 5.08
FULC (FULC) Monthly Stock Prediction for 2023
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Dec. | 5.61 | 5.03 | 5.83 | 13.65 |
Fulcrum Therapeutics forecast for this year
Fulcrum Therapeutics Stock Prediction for Dec 2023
An uptrend is forecast for this month with an optimal target price of $5.6064. Pessimistic: $5.03. Optimistic: $5.83
Fulcrum Therapeutics (FULC) Monthly Stock Prediction for 2024
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 5.93 | 5.07 | 6.45 | 21.51 |
| Mar | 6.33 | 5.49 | 7.25 | 24.30 |
| Mar | 6.18 | 5.66 | 6.44 | 12.09 |
| Apr | 5.17 | 4.85 | 5.78 | 16.10 |
| May | 5.61 | 4.77 | 6.42 | 25.70 |
| Jun | 5.43 | 5.05 | 5.94 | 14.99 |
| Jul | 5.03 | 4.75 | 5.68 | 16.31 |
| Aug | 5.48 | 5.11 | 6.04 | 15.43 |
| Sep | 5.56 | 5.25 | 6.17 | 14.95 |
| Oct | 5.39 | 4.91 | 5.86 | 16.21 |
| Nov | 4.35 | 4.07 | 4.61 | 11.70 |
| Dec | 4.37 | 4.02 | 5.02 | 20.03 |
Fulcrum Therapeutics (FULC) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 5.10 | 4.74 | 5.30 | 10.58 |
| Mar | 5.24 | 4.53 | 5.78 | 21.60 |
| Mar | 5.06 | 4.48 | 5.78 | 22.59 |
| Apr | 5.50 | 5.06 | 6.19 | 18.29 |
| May | 5.93 | 5.13 | 6.32 | 18.76 |
| Jun | 5.50 | 4.82 | 5.74 | 16.09 |
| Jul | 4.48 | 4.25 | 5.12 | 16.96 |
| Aug | 3.59 | 3.34 | 3.74 | 10.75 |
| Sep | 3.83 | 3.29 | 4.30 | 23.53 |
| Oct | 3.48 | 3.25 | 3.63 | 10.54 |
| Nov | 3.40 | 2.92 | 3.77 | 22.52 |
| Dec | 3.24 | 2.83 | 3.53 | 19.85 |
Fulcrum Therapeutics (FULC) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 3.30 | 2.98 | 3.71 | 19.72 |
| Mar | 3.31 | 3.07 | 3.63 | 15.48 |
| Mar | 3.63 | 3.41 | 3.99 | 14.57 |
| Apr | 4.00 | 3.37 | 4.22 | 20.08 |
| May | 4.30 | 3.75 | 4.77 | 21.44 |
| Jun | 4.12 | 3.49 | 4.51 | 22.49 |
| Jul | 4.71 | 4.34 | 4.94 | 12.21 |
| Aug | 5.44 | 4.88 | 5.98 | 18.36 |
| Sep | 6.16 | 5.63 | 6.40 | 12.12 |
| Oct | 6.40 | 5.95 | 7.41 | 19.69 |
| Nov | 6.95 | 6.62 | 8.02 | 17.50 |
| Dec | 6.49 | 5.82 | 6.90 | 15.63 |
Fulcrum Therapeutics (FULC) Monthly Stock Prediction for 2027
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 7.46 | 7.07 | 8.26 | 14.44 |
| Mar | 8.54 | 7.30 | 9.11 | 19.89 |
| Mar | 8.10 | 7.78 | 9.28 | 16.23 |
| Apr | 8.76 | 7.82 | 9.78 | 20.07 |
| May | 8.54 | 7.84 | 9.56 | 18.04 |
| Jun | 8.45 | 7.91 | 9.52 | 16.87 |
| Jul | 8.76 | 7.35 | 9.74 | 24.46 |
| Aug | 8.97 | 7.76 | 10.06 | 22.82 |
| Sep | 8.59 | 7.87 | 9.40 | 16.27 |
| Oct | 9.76 | 8.61 | 10.36 | 16.95 |
| Nov | 11.49 | 9.95 | 12.80 | 22.26 |
| Dec | 12.44 | 11.27 | 13.71 | 17.79 |
Fulcrum Therapeutics information and performance
26 LANDSDOWNE STREET, CAMBRIDGE, MA, US
Market capitalization of the Fulcrum Therapeutics, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of FULC shares in the company outstanding by the market price of one share.
EBITDA of Fulcrum Therapeutics is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
